Cargando…

Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy

BACKGROUND: Although CD4 cell count monitoring is used to decide when to start antiretroviral therapy in patients with HIV-1 infection, there are no evidence-based recommendations regarding its optimal frequency. It is common practice to monitor every 3 to 6 months, often coupled with viral load mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Buclin, Thierry, Telenti, Amalio, Perera, Rafael, Csajka, Chantal, Furrer, Hansjakob, Aronson, Jeffrey K., Glasziou, Paul P.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072996/
https://www.ncbi.nlm.nih.gov/pubmed/21494630
http://dx.doi.org/10.1371/journal.pone.0018578
_version_ 1782201606739066880
author Buclin, Thierry
Telenti, Amalio
Perera, Rafael
Csajka, Chantal
Furrer, Hansjakob
Aronson, Jeffrey K.
Glasziou, Paul P.
author_facet Buclin, Thierry
Telenti, Amalio
Perera, Rafael
Csajka, Chantal
Furrer, Hansjakob
Aronson, Jeffrey K.
Glasziou, Paul P.
author_sort Buclin, Thierry
collection PubMed
description BACKGROUND: Although CD4 cell count monitoring is used to decide when to start antiretroviral therapy in patients with HIV-1 infection, there are no evidence-based recommendations regarding its optimal frequency. It is common practice to monitor every 3 to 6 months, often coupled with viral load monitoring. We developed rules to guide frequency of CD4 cell count monitoring in HIV infection before starting antiretroviral therapy, which we validated retrospectively in patients from the Swiss HIV Cohort Study. METHODOLOGY/PRINCIPAL FINDINGS: We built up two prediction rules (“Snap-shot rule” for a single sample and “Track-shot rule” for multiple determinations) based on a systematic review of published longitudinal analyses of CD4 cell count trajectories. We applied the rules in 2608 untreated patients to classify their 18 061 CD4 counts as either justifiable or superfluous, according to their prior ≥5% or <5% chance of meeting predetermined thresholds for starting treatment. The percentage of measurements that both rules falsely deemed superfluous never exceeded 5%. Superfluous CD4 determinations represented 4%, 11%, and 39% of all actual determinations for treatment thresholds of 500, 350, and 200×10(6)/L, respectively. The Track-shot rule was only marginally superior to the Snap-shot rule. Both rules lose usefulness for CD4 counts coming near to treatment threshold. CONCLUSIONS/SIGNIFICANCE: Frequent CD4 count monitoring of patients with CD4 counts well above the threshold for initiating therapy is unlikely to identify patients who require therapy. It appears sufficient to measure CD4 cell count 1 year after a count >650 for a threshold of 200, >900 for 350, or >1150 for 500×10(6)/L, respectively. When CD4 counts fall below these limits, increased monitoring frequency becomes advisable. These rules offer guidance for efficient CD4 monitoring, particularly in resource-limited settings.
format Text
id pubmed-3072996
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-30729962011-04-14 Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy Buclin, Thierry Telenti, Amalio Perera, Rafael Csajka, Chantal Furrer, Hansjakob Aronson, Jeffrey K. Glasziou, Paul P. PLoS One Research Article BACKGROUND: Although CD4 cell count monitoring is used to decide when to start antiretroviral therapy in patients with HIV-1 infection, there are no evidence-based recommendations regarding its optimal frequency. It is common practice to monitor every 3 to 6 months, often coupled with viral load monitoring. We developed rules to guide frequency of CD4 cell count monitoring in HIV infection before starting antiretroviral therapy, which we validated retrospectively in patients from the Swiss HIV Cohort Study. METHODOLOGY/PRINCIPAL FINDINGS: We built up two prediction rules (“Snap-shot rule” for a single sample and “Track-shot rule” for multiple determinations) based on a systematic review of published longitudinal analyses of CD4 cell count trajectories. We applied the rules in 2608 untreated patients to classify their 18 061 CD4 counts as either justifiable or superfluous, according to their prior ≥5% or <5% chance of meeting predetermined thresholds for starting treatment. The percentage of measurements that both rules falsely deemed superfluous never exceeded 5%. Superfluous CD4 determinations represented 4%, 11%, and 39% of all actual determinations for treatment thresholds of 500, 350, and 200×10(6)/L, respectively. The Track-shot rule was only marginally superior to the Snap-shot rule. Both rules lose usefulness for CD4 counts coming near to treatment threshold. CONCLUSIONS/SIGNIFICANCE: Frequent CD4 count monitoring of patients with CD4 counts well above the threshold for initiating therapy is unlikely to identify patients who require therapy. It appears sufficient to measure CD4 cell count 1 year after a count >650 for a threshold of 200, >900 for 350, or >1150 for 500×10(6)/L, respectively. When CD4 counts fall below these limits, increased monitoring frequency becomes advisable. These rules offer guidance for efficient CD4 monitoring, particularly in resource-limited settings. Public Library of Science 2011-04-08 /pmc/articles/PMC3072996/ /pubmed/21494630 http://dx.doi.org/10.1371/journal.pone.0018578 Text en Buclin et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Buclin, Thierry
Telenti, Amalio
Perera, Rafael
Csajka, Chantal
Furrer, Hansjakob
Aronson, Jeffrey K.
Glasziou, Paul P.
Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy
title Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy
title_full Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy
title_fullStr Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy
title_full_unstemmed Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy
title_short Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy
title_sort development and validation of decision rules to guide frequency of monitoring cd4 cell count in hiv-1 infection before starting antiretroviral therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072996/
https://www.ncbi.nlm.nih.gov/pubmed/21494630
http://dx.doi.org/10.1371/journal.pone.0018578
work_keys_str_mv AT buclinthierry developmentandvalidationofdecisionrulestoguidefrequencyofmonitoringcd4cellcountinhiv1infectionbeforestartingantiretroviraltherapy
AT telentiamalio developmentandvalidationofdecisionrulestoguidefrequencyofmonitoringcd4cellcountinhiv1infectionbeforestartingantiretroviraltherapy
AT pererarafael developmentandvalidationofdecisionrulestoguidefrequencyofmonitoringcd4cellcountinhiv1infectionbeforestartingantiretroviraltherapy
AT csajkachantal developmentandvalidationofdecisionrulestoguidefrequencyofmonitoringcd4cellcountinhiv1infectionbeforestartingantiretroviraltherapy
AT furrerhansjakob developmentandvalidationofdecisionrulestoguidefrequencyofmonitoringcd4cellcountinhiv1infectionbeforestartingantiretroviraltherapy
AT aronsonjeffreyk developmentandvalidationofdecisionrulestoguidefrequencyofmonitoringcd4cellcountinhiv1infectionbeforestartingantiretroviraltherapy
AT glaszioupaulp developmentandvalidationofdecisionrulestoguidefrequencyofmonitoringcd4cellcountinhiv1infectionbeforestartingantiretroviraltherapy